Trial Profile
A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled First-in-human Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06648671 After Administration Of Single Ascending Doses To Fasted And Fed Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs PF 6648671 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 17 Jul 2019 PKPD model was developed to characterize the differential effects of PF 06648671 on the various CSF species in healthy humans using data from three phase I studies (NCT02316756, NCT02440100 and NCT02407353 ); results published in the Clinical Pharmacology and Therapeutics
- 20 Jul 2017 Results of 3 phase 1 studies assessing plasma exposure and cerebrospinal fluid response relationship in healthy subjects, presented at the Alzheimer's Association International Conference 2017.
- 01 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov